Tamoxifen exhibits favorable effects on the lipid and lipoprotein profile since it decreases the total and LDL cholesterol levels as well as the Lp(a) levels. Additionally, a small increase in serum triglycerides is commonly found after tamoxifen administration. However, severe hypertriglyceridemia which can sometimes be associated with life-threatening complications is occasionally noticed. Herein, we describe a patient who developed tamoxifeninduced severe hypertriglyceridemia and pancreatitis. An analysis of the underlying pathogenetic mechanisms as well as a review of the relevant literature is also provided.
Introduction
Tamoxifen-citrate, a non-steroidal antiestrogen, is one of the most widely used hormonal treatments for patients with breast cancer. Recent studies in pre-and postmenopausal women have shown that tamoxifen exhibits favorable effects on the lipid and lipoprotein profile by decreasing the total and LDL cholesterol levels as well as the Lp(a) levels [1] [2] [3] [4] . It has been suggested that its estrogenic activity is mainly responsible for the observed changes in lipid parameters [5, 6] . Consequently, an increased VLDL synthesis leading to increased triglyceride levels is expected after tamoxifen administration [7, 8] . In fact, a small though insignificant increase in serum triglycerides is commonly found [2, 3, [9] [10] [11] . However, marked hypertriglyceridemia sometimes associated with life-threatening complications is occasionally reported after tamoxifen administration [12] [13] [14] [15] [16] [17] [18] . We describe a patient who developed tamoxifen-induced severe hypertriglyceridemia and pancreatitis.
Case report
A 53-year-old female patient had a radical mastectomy for breast cancer in January 1998, followed by six courses of adjuvant chemotherapy with CMF (cyclophosphamide, methotrexate and 5-fluorouracil). After the end of chemotherapy, tamoxifen was started at a dose of 20 mg/day orally. Eight months later, the patient was admitted to our Department with severe epigastric discomfort, nausea and vomiting. The serum amylase level was markedly increased (1600 IU/1, normal values < 100 IU/1) and a diagnosis of pancreatitis was made. The patient's serum was grossly lipemic and serum triglycerides and cholesterol levels were markedly increased (5200 mg/dl and 1800 mg/dl, respectively). The patient was treated symptomatically with volume repletion and meperidine for pain relief. Tamoxifen was discontinued and the patient was commenced on oral gemfibrozil 600 mg twice daily. Five days later she was free of abdominal pain, the serum amylase was normal and the triglycerides were significantly reduced to 1650 mg/dl.
On reviewing her medical history it was apparent that she probably had a genetically determined hyperlipidemia. Specifically, even though no lipid determinations had been carried out either before or after tamoxifen administration, it was repeatedly reported that her serum was lipemic in the routine laboratory investigations performed during the follow-up. Additionally, her sister had mixed hyperlipidemia and her daughter, aged 29 years, was found to have increased triglycerides few months ago. However, the patient's severe hypertriglyceridemia did not follow any dietary deviation or alcohol consumption.
The patient was discharged on the 14th day of hospitalization with total cholesterol 736 mg/dl, HDL cholesterol 28 mg/dl and triglycerides 1250 mg/dl. One month later and while she was on hypolipidemic diet and gemfibrozil treatment, serum lipid parameters were as follows: total cholesterol 268 mg/dl HDL cholesterol 48 mg/dl, and triglycerides 450 mg/dl.
Discussion
Our patient developed severe hypertriglyceridemia after tamoxifen administration resulting in acute pancreatitis. There is evidence that tamoxifen can cause hypertriglyceridemia in susceptible individuals; that is, in patients with distrubances of triglyceride -rich lipoproteins metabolism [7] . This may be analogous to the chylomicronemia associated with estrogenic drugs. Even though no lipid determinations were carried out in the patient before drug administration, it is suspected that she had had increased triglyceride levels, since the serum was reported to be lipemic and the patient continued to have significant hypertriglyceridemia after drug cessation and gemfibrozil treatment. Additionally, a family history of mixed dyslipidemia was obtained possibly suggesting familial combined hyperlipidemia. Interestingly, delayed severe hypertriglyceridemia was evident, as it was previously reported in another case [15] . Tamoxifen may need rather prolonged therapy to increase triglyceride concentration, since short-term studies [2, 19, 20] failed to observe any changes in serum triglyceride levels. Thus, dangerous lipid abnormalities may occur months or years during therapy and therefore it would seem prudent to monitor fasting lipids in patients on tamoxifen, especially in patients with endogenous dyslipidemia (familial hypertriglyceridemia or familial combined hyperlipidemia).
In the literature there are few cases of severe hypertriglyceridemia (triglycerides > 1000 mg/dl) after tamoxifen administration (Table 1) [12] [13] [14] [15] [16] [17] [18] . The vast majority of these patients had previously had hypertriglyceridemia, while when a family history is provided, a strong family history of dyslipidemia was evident. Additionally, diabetes or impaired glucose tolerance may have contributed to the development of severe hyperlipidemia in some cases, while the role of apolipoprotein E phenotype in this setting is disputable [1, 16] .
Tamoxifen, like estrogens, stimulates the synthesis and secretion from the liver of very low density lipoprotein (VLDL), which is the main circulating carrier of triglycerides [17, [22] [23] [24] , while it decreases VLDL and intermediate-density lipoprotein (IDL) catabolism as a result of decreasing lipoprotein and hepatic lipase activities [17, [23] [24] [25] . However, the drug can induce only modest elevations in serum triglycerides in normolipidemic patients, having an intact ability to catabolise lipoproteins, even though it has recently been reported that marked hypertriglyceridemia may also occur even in normolipidemic patients [23] . On the other hand, tamoxifen can cause a significant increase in serum triglycerides in patients who also exhibit an underlying endogenous or exogenous distrubance of the triglyceriderich lipoproteins metabolism. In fact, since the removal of serum triglycerides is a saturatable process, when some patients with a pre-existing hyperlipoproteinemia and serum triglyceride levels near the point of saturation before treatment are put on tamoxifen, large increases in lipid levels can occur, as it was the case in our patient a well as in the other reported cases shown in Table 1 [12] [13] [14] [15] [16] [17] [18] .
Interestingly, only four cases of severe hypertriglyceridemia -induced pancreatitis and one case with abdominal pain have also been reported, including ours. Although three patients recovered with tamoxifen withdrawal, diet and hypolipidemic drugs, the fourth patient had fulminant pancreatitis and died of multiorgan failure [13, 14, 16] . In most reported cases, the increased serum triglycerides returned to pre-treatment values after stopping tamoxifen. However, in some patients with very high triglyceride concentrations hypolipidemic drugs, namely fibrates, were necessary, as it was in our case [14] [15] [16] [17] . These drugs were very effective in these patients because of their ability to decrease serum triglyceride levels.
It is concluded that tamoxifen should be used with extreme caution in patients who exhibit increased triglycerides in the fasting state before therapy is started, because the weak estrogenic activity can cause severe and possibly life-threatening hyperlipidemia.
